Related Experiment Videos
Indication of an antipsychotic action of the opiate antagonist naloxone
Abstract:
In 20 psychotic patients with frequent hallucinations and/or actual delusional experience a possible antipsychotic action of the opiate antagonist naloxone (N-allyl-noroxymorphone) was investigated, using a double-blind placebo-controlled cross-over design. 18 of these patients were not treated with neuroleptic drugs; 13 suffered from an acute episode of schizophrenia. Psychopathological changes were assessed by the use of the IMPS-scale and of a symptom-specific rating scale (VBS). Intravenous injection of naloxone (in most cases 4.0 mg) induced a reduction of psychotic symptomatology (especially hallucinations) in the majority of patients. Compared with placebo this effect reached statistical significance within 2-7 hours after injection. From this result a possible involvement of endogenous ligands of opiate receptors in the pathogenesis of schizophrenia may be concluded.
Insights
The opiate antagonist naloxone significantly reduced psychotic symptoms, particularly hallucinations, in patients with schizophrenia. This suggests a potential role for endogenous opiates in the development of schizophrenia.
Area of Science:
- Neuroscience
- Psychiatry
- Pharmacology
Background:
- Schizophrenia is a complex psychiatric disorder characterized by hallucinations and delusions.
- The role of endogenous opioid systems in psychosis remains an area of investigation.
Purpose of the Study:
- To investigate the potential antipsychotic effects of naloxone, an opiate antagonist, in patients experiencing psychotic symptoms.
- To explore the involvement of endogenous opioid pathways in the pathophysiology of schizophrenia.
Main Methods:
- A double-blind, placebo-controlled, cross-over study design was employed.
- Twenty patients with frequent hallucinations and/or delusions were included.
- Psychopathological changes were assessed using the IMPS scale and the VBS rating scale.
Main Results:
- Intravenous administration of naloxone (4.0 mg) led to a reduction in psychotic symptomatology, notably hallucinations, in most patients.
- This therapeutic effect was statistically significant compared to placebo within 2-7 hours post-injection.
- The observed effects were particularly noted in patients not on neuroleptic treatment and those with acute schizophrenia episodes.
Conclusions:
- Naloxone demonstrates a potential antipsychotic action, particularly in alleviating hallucinations.
- The findings suggest a possible involvement of endogenous ligands of opiate receptors in the pathogenesis of schizophrenia.
- Further research into the neurobiological mechanisms underlying schizophrenia and the role of the endogenous opioid system is warranted.